Available option
5mg
Lyophilised powder
- Strength
- 5mg
- Format
- Lyophilised powder
Bear Biotech catalogue
PTD-DBM
CXXC5–Dishevelled interaction competitor peptide research material
- CXXC5–Dvl interaction
- Wnt/β-catenin signalling
- Preclinical regeneration models
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is PTD-DBM?
PTD-DBM is a cell-penetrating competitor peptide developed to disrupt the CXXC5–Dishevelled interaction, a negative-feedback element in Wnt/β-catenin signalling. Research interest is concentrated in preclinical regeneration, fibroblast and wound-model biology. No established human therapeutic evidence exists.
Preclinical cell and animal research only.
Research focus
Key research areas
PTD-DBM research: targeting CXXC5–Dishevelled signalling
PTD-DBM is a cell-penetrating competitor peptide designed to interfere with the CXXC5–Dishevelled interaction. Published work remains preclinical. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- CXXC5–Dvl interaction
- Wnt/β-catenin signalling
- Preclinical regeneration models
Representative primary research
Representative research
Research examines CXXC5-mediated negative feedback, Dishevelled binding, β-catenin signalling, fibroblast/keratinocyte responses and mouse wound-regeneration models.
- CXXC5 negatively regulates cutaneous wound healing ↗ Cell and mouse preclinical study; sequence and lot identity remain controlling.
- PTD-DBM hydrogel regenerative wound-healing model ↗ Mouse preclinical study; it does not establish human outcomes or catalogue material identity.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- PTD-DBM
- Research category
- CXXC5–Dishevelled interaction competitor peptide research material
- Evidence position
- Preclinical cell and animal research only.
- Recorded formats
- Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
How is PTD-DBM designed to affect the CXXC5–Dvl interaction?
PTD-DBM is studied as a designed material targeting the CXXC5-Dvl interaction within Wnt/beta-catenin signalling. Research interest is confined to preclinical regeneration models.
What does Wnt and beta-catenin signalling contribute to PTD-DBM models?
Wnt/beta-catenin experiments assess pathway and tissue-model endpoints after disrupting CXXC5-Dvl interaction. They do not establish a human regenerative outcome.
Why is PTD-DBM evidence limited to preclinical regeneration research?
Published PTD-DBM findings come from defined cell and animal models examining CXXC5–Dishevelled and Wnt/β-catenin signalling. No established human therapeutic evidence is available, so conclusions must remain limited to those preclinical models.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.